Developing a ‘theranostic’ nanocluster to diagnose and treat superficial EGFR+ bladder cancer. These nanoclusters, which are coated with gold nanorods, will target cancer lesions with anti-EGFR mAb. The nanorods will ablate lesions upon light stimulation.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Colorado
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Multifunctional Nanoclusters
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
